Physician profile
Olivia Elder
NPI 1053929422
$3,245.40
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,197 · 2022: $1,946 · 2023: $61.00 · 2024: $41.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $102.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mml US, INC. | $1,513.70 | 2022 | |
| Medtronic, INC. | $228.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $217.05 | 2021-2023 | Farxiga |
| Relievant Medsystems, INC. | $143.36 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $135.47 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $122.82 | 2021-2022 | |
| Optinose US, INC. | $117.57 | 2021 | |
| Glaxosmithkline, LLC. | $114.57 | 2021 | |
| Genzyme Corporation | $114.08 | 2021 | |
| Novartis Pharmaceuticals Corporation | $86.44 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $80.32 | 2021 | |
| Covis Pharma Gmbh | $76.99 | 2021 | |
| Abbvie INC. | $57.16 | 2022-2024 | |
| Novo Nordisk INC | $47.26 | 2022-2023 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.64 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $22.43 | 2021 | |
| Pfizer INC. | $22.13 | 2021 | |
| Alk-Abello, INC | $20.08 | 2021 | |
| Amgen INC. | $16.32 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.52 | 2021 | |
| Mylan Specialty L.P. | $15.05 | 2021 | |
| Csl Behring | $14.52 | 2021 | |
| Merck Sharp & Dohme LLC | $12.74 | 2021 | |
| Eyevance Pharmaceuticals LLC | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olivia Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.